Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines

Abstract

Background

Plant-made biotherapeutics are gathering momentum and some plant glycoproteins are allergens. Glycans with core β1-2xylose and α1,3fucose motifs and antennae terminated by mannose residues (e.g.: MMXF) are found on several plant allergens and can cross-react with glyco-epitopes from other sources. To date, reactivity to these cross-reactive determinants has not been associated with clinical symptoms.

Objective

We produced VLP vaccines bearing the hemagglutinin(HA) of H5(A/Indonesia/5/05) or H1(A/California/07/09) influenza viruses by transfection of Nicotiana benthamiana. Subjects enrolled in Phase I/II trials were followed for evidence of allergy/hypersensitivity and development of antibodies against plant glyco-epitopes.

Methods

A total of 280/349 subjects received either one (H1) or 2 doses (H5) of vaccine (5–45 μg of HA/dose) intramuscularly including 40 with pre-existing plant allergies. Subjects were monitored for 6 months. IgG and IgE to plant glyco-epitopes were measured by ELISA using corn-/egg-derived avidin and bromelain as target antigens.

Results

No subject developed allergic/hypersensitivity symptoms. Some (34%) developed transient IgG and, in some cases IgE, to plant glyco-epitopes but no subject mounted an IgE response to the MMXF motif. Antibodies returned to baseline by 6 months in most subjects.

Conclusion

VLP vaccines bearing influenza HA glycoproteins can elicit transient IgG and, in some cases, IgE responses that are not associated with either the development or worsening of allergic/hypersensitivity symptoms.

Introduction

Plant-based production of recombinant proteins for human therapeutic and preventive uses is nearing an important milestone with several products in late-stage clinical development [1], [2]. One product, a recombinant glucocerebrosidase produced in carrot cells for the treatment of Gaucher disease (Protalix™) received FDA approval in 2012.

Plant glycoproteins contain structural motifs not found on human glycoproteins (e.g.: core β1-2xylose and α1-3fucose). Since some of these motifs occur on known plant allergens, one theoretical risk of using plants for production of biotherapeutics is the induction of hypersensitivity. Many plant allergenic glyco-epitopes share biochemical and structural homology with epitopes found on glycoproteins from other sources (e.g.: insects, arthropods): so-called cross-reactive carbohydrate determinants (CCDs). Such CCDs can be involved in the binding of IgE and release of histamine by mast cells [3], [4]. Roughly 20% of subjects with pollen and food allergies display in vitro CCD reactivity based on β1-2xylose or α1-3fucose. However, IgEs directed against CCDs appear to have little clinical significance, even in allergy-prone individuals [5], [6], [7].

Fortunately, only a small fraction of environmental proteins are allergenic and both experimental and computational studies suggest that allergen cross-reactivity is attributable primarily to protein sequence and structural similarities [8]. Although carbohydrates could theoretically contribute to such conformational epitopes, a recent study of CCD-reduced food allergens (i.e. less β1-2xylose and α1-3fucose) demonstrated that in vivo reactivity is largely driven by peptide- and not CCD-specific IgEs [9].

Despite the innocuous nature of most plant glycans, a small number of plant-specific glycans have been associated with IgE induction and clinical symptoms. Although there are exceptions [7], these allergens typically have complex glycans with core β1-2xylose and α1-3fucose and antennae terminated by mannose residues (e.g.: MMFX or MUFX). However, the presence of these motifs does not always lead to clinically-apparent allergic responses. For example, a recombinant human lactoferrin produced in transgenic rice plants containing these glycans [10] has recently been evaluated as a nutritional supplement. Almost all (82.7%) of the 29 subjects with pollen and food allergies had detectable IgE specific for rice-derived lactoferrin [11]. Although these IgEs had in vitro reactivity in a basophil histamine release assay, no subject challenged orally with 1 g of the rice-derived lactoferrin had an allergic reaction. Although antigen-specific IgE is generally accepted as a risk factor for type-I hypersensitivity, this study suggests a lower predictive value for IgE directed against plant glycans, for oral exposures at least. Indeed, orally-administered, plant-made vaccines have an excellent track record of safety [12]. The glycans found on most plant glycoproteins are typically more complex than the simple MUXF and MMXF motifs (Table 1).

In summary, most plant glycoprotein allergens have biochemical and structural characteristics associated with cross-reactivity that are not generally found on benign plant glycoproteins. Although some of these CCDs can lead to IgE-mediated histamine release ex vivo in patients with plant allergies, their clinical significance is uncertain. The allergenic nature of most of these plant glycoproteins is likely driven by the protein backbone rather than the glycan motifs.

In the current work, we measured IgG and IgE responses to plant glycans pre- and post-vaccination in two clinical trials, a Phase I of an H1 monovalent VLP vaccine and a Phase II of an H5 monovalent VLP vaccine.